Description & Prevention of Omicron

Open Access

Year : 2022 | Volume : | Issue : 2 | Page : 5-16
By

    Suhail M.

  1. Blessy Jacob

  2. Visaga Perumal

  3. Vineeth Chandy

  1. Student, Department of Pharmaceutical Chemistry, T. John College of Pharmacy, Karnataka, India

Abstract

November 9, 2021, Botswana becomes the first country to recognise it (Nov 11 2021). The new variant (B.1.529) has been represented in 77 countries. Omicron presents 32 changes in spike protein Scribd, restricting the point of interaction with the ACE2 receptor protein. Computational shows and components’ recreation has been applied to investigate the collaboration between the SARS-CoV-2 RBD and the ACE2 receptor. The receptor-binding domain (RBD), which more barely joins the ACE2 receptor in the omicron variety; this uncovered that the ACE2 receptor displays an improved restricting profile towards the S protein of the omicron variation when contrasted with the Delta variation. We initiated the changes either by cancellation, modification, or expansion to explain the all-around expected plan of S-protein for the Omicron variety, utilising the Alpha fold with 1268 amino acids, where the Omicron variation showed more than 30 transformations at various locals of S protein. We played out the phylogenetic investigation of all SARS-COV-2 variations, given that spike S protein introduced the longest transformative distance compared to other variants. The non-identical cluster arrangements shown by the omicron (VOC) and omicron S proteins contain 34 amino acid corrosive (AA) changes. AlphaFold2 is an open-source computational methodology created to assist us with obtaining exact protein structures given hereditary information. The progressions in the S, M, and N proteins of the as of late recognized SARS-CoV-2 Omicron assortment were contemplated, and various amino acids on RBD were adjusted, which might influence the collaboration between the RBD and ACE2, while the S309 immunizer may in any case be viable in killing Omicron RBD. The SARS-CoV-2 is classified as VOI (a variant of interest) and VOC (a variant of concern). The Omicron will come under the VOC because of its omicron-containing mutation gene. A SARS-CoV-2 VOI is a SARS- CoV-2 variation with innate changes that are expected or alluded to impact contamination characteristics like getting ailment reality and immune take off, suggestive or helpful break. The SARS- CoV-2 VOC (a variant of concern) is a SARS-CoV-2 variety that meets the importance of a VOI (a variant of interest) and is estimated through a similar estimation. The omicron cases in India are increasing every day in every state of India, especially Maharashtra, Karnataka, Kerala, Delhi, etc. Immunization with BNT162b2 has been shown to prompt killing sum neutralizer against the familial infection of 2.4-overlay of the mean gaining strength sum. It compromises the ability of the counter-acting agent to guarantee against contamination. In any case, much lower balance levels are adequate for insurance against serious infection. The Pfizer-Biotech immunisation could be essentially diminished against omicron with a 41-overlay lower level of killing neutralizer when contrasted with a variation of infection when compared with the previous variant characterised by spike protein substitution D614G. The third doses of the Pfizer immunization give a comparative degree of killing neutralizer against omicron as seen after two dosages against the first infection. When compared to wild types, individuals who received two doses of vaccine demonstrated a more than a 25-point decrease in balance titres against omicron suggesting that two dosages of the Pfizer vaccine may not be adequate to safeguard against illness with the omicron variety. The support piece of the ongoing vaccination grows the counter acting agent focus by 25-cross-over.

Keywords: Omicron, SARS-CoV-2, mutations, binding, RBD, ACE2, classification, VOI, VOC, characterization, statistics, diagnosis, vaccines, neutralization, Pfizer, prevention

[This article belongs to Research & Reviews: A Journal of Pharmacognosy(rrjopc)]

How to cite this article: Suhail M., Blessy Jacob, Visaga Perumal, Vineeth Chandy Description & Prevention of Omicron rrjopc 2022; 9:5-16
How to cite this URL: Suhail M., Blessy Jacob, Visaga Perumal, Vineeth Chandy Description & Prevention of Omicron rrjopc 2022 {cited 2022 Aug 22};9:5-16. Available from: https://journals.stmjournals.com/rrjopc/article=2022/view=90082

Full Text PDF Download

Browse Figures

References

1. Genovese L, Zaccaria M, Farzan M, Johnson W, Momeni B. Investigating the mutational landscape of the SARS-CoV-2 Omicron variant via ab initio quantum mechanical modeling. BioRxiv. 2021.
2. Zhang L, Li Q, Liang Z, et al. The significant immune escape of pseudotyped SARS-CoV-2 Variant Omicron. Emerg Microbes Infect. 2021; 11(1): 1–5.
3. Kannan SR, Spratt AN, Sharma K, et al. Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies. J Autoimmun. 2022; 126: 102779.
4. Karim SS, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021; 398(10317): 2126–8.
5. Huang X, Pearce R, Zhang Y. De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2. Aging (Albany NY). 2020; 12(12): 11263.
6. Swift T, People M. ACE2: entry receptor for SARS-CoV-2. Science. 2020 Mar 27; 367(6485): 1444–8.
7. Wang Y, Liu M, Gao J. Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. Proc Natl Acad Sci. 2020; 117(25): 13967–74.
8. Lupala CS, Li X, Lei J, et al. Computational simulations reveal the binding dynamics between human ACE2 and the receptor binding domain of SARS-CoV-2 spike protein. bioRxiv. 2020.
9. Xu X, Chen P, Wang J. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020; 63(3): 457–60.
10. Damas J, Hughes GM, Keough KC, et al. Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates. Proc Natl Acad Sci. 2020; 117(36): 22311–22.
11. Vickers NJ. Animal communication: when I’m calling you, will you answer too? Curr Biol. 2017; 27(14): R713–5.
12. Lupala CS, Ye Y, Chen H, Su XD, et al. Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor. Biochem Biophys Res Commun. 2022; 590: 34–41.
13. Sadek A, Zaha D, Ahmed MS. Structural Insights of SARS-CoV-2 Spike Protein from Delta and Omicron Variants. bioRxiv. 2021.
14. Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020; 181(2): 281–92.
15. Jumper J, Evans R, Pritzel A, Green T, et al. Highly accurate protein structure prediction with Alpha Fold. Nature. 2021; 596(7873): 583–9.
16. Yang Q, Syed AA, Fahira A, Shi Y. Structural analysis of the SARS-CoV-2 Omicron variant proteins. Research. 2021; 2021: 9769586.
17. Mohapatra Ranjan K, Tiwari Ruchi, Sarangi Ashish K, et al. Omicron (B.1.1.529) variant of SARS-CoV-2: Concerns, challenges, and recent updates. Wiley online library, J Med Virol. 2022; 94(6): 2336–2342.
18. India Today. (2022 Jan 7). Covid cases in India: Nation records 1 lakh daily patients after seven months. [Online]. https://www.indiatoday.in/coronavirus-outbreak/story/covid-in-india-omicron- surge-deaths-new-cases-lockdown-restrictions-1897077-2022-01-07; last updated Jan 2022.
19. Xueying Wang, Yang Zhou, Linlin Ma. Coronavirus Disease 2019 (COVID-19): Diagnosis and prognosis. Blood Genom. 2020; 4(2): 96–107.
20. Ettaboina SK, Nakkala K, Laddha KS. A Mini Review on SARS-COVID-19-2 Omicron Variant (B. 1.1. 529). SciMed J. 2021; 3(4): 399–406.
21. Haldar B. Evaluating the risk factor of novel public health disaster “omicron” variant: an Indian perspective. Model Earth Syst Environ. 2022; 1–6.
22. Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med. 2022; 28(3): 486–489.


Regular Issue Open Access Article
Volume 9
Issue 2
Received June 22, 2022
Accepted July 25, 2022
Published August 22, 2022